Oblique Therapeutics AB

Oblique Therapeutics AB
Quotes
Change country

Follow us:
Share:
Subscribe:

Links

Website

Quotes

First of all, it is an honor to be recognized by ESMO, and we are thrilled to exhibit our promising results for OT-1096 for the first time. Even more so, being part of changing the treatment landscape for cancer at this time is exciting for us: the 2018 Nobel Prize in Medicine was awarded for pioneering work in immunooncology and we see more and more traction and exciting results from novel immunomodulatory small molecules, such as ours, with the capacity to favorably change the immune system inside tumors.

Prof. Owe Orwar, CEO at Oblique Therapeutics.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Oblique Therapeutics present tumor growth inhibition and Treg-lowering data for OT-1096 in humanized mouse TNBC model at oncology congress ESMO

Tue, Oct 09, 2018 09:00 CET

Gothenburg, 09 Oct 2018 – Oblique Therapeutics, a biotech focused on new medicines for severe diseases with large unmet medical needs, today announced that it will present new promising preclinical data for the drug candidate OT-1096 in triple-negative breast cancer (TNBC) at the largest oncology congress in Europe, the European Society for Medical Oncology (ESMO), held 19-23 October in Munich, Germany.The new data of the first-in-class anti-cancer agent OT-1096 shows promising preliminary results with improved tumor growth inhibition compared to pembrolizumab, one of the blockbuster drugs

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

Links

Quotes

Oblique Therapeutics present tumor growth inhibition and Treg-lowering data for OT-1096 in humanized mouse TNBC model at oncology congress ESMO

Subscribe